Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exagen Inc. - Common Stock (NQ:XGN)

4.239 +0.409 (+10.68%)
Streaming Delayed Price Updated: 3:43 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Exagen (XGN) Q1 2026 Earnings Transcript ↗
Exagen (XGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Exagen Q1 Earnings Call Highlights ↗
Exagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician... 
Via MarketBeat
Topics Earnings
Exagen Inc. (NASDAQ:XGN) Soars on Q1 2026 Earnings Beat as Record Revenue and Narrowed Loss Fuel Pre-Market Rally ↗
Via Chartmill
Topics Earnings
News headline image
Exagen Inc. Reports First Quarter 2026 Results
Delivers record total revenue and AVISE(R) CTD average selling price 
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. (NASDAQ:XGN) Reports Record 2025 Revenue and Provides 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 4 Analysts Discuss Exagen Stock ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Exagen Stock ↗
 
Via Benzinga
News headline image
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Upcoming Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Select Preliminary 2025 Financial Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. (NASDAQ:XGN) Reports Mixed Q3 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗
Exagen's Q3 2025 results show a revenue beat but a wider-than-expected loss, causing a pre-market stock decline. 
Via Chartmill
News headline image
Exagen Inc. Reports Strong Q3 2025 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
From Exagen Inc.
Via GlobeNewswire
News headline image
Demystifying Exagen: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Third Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Exagen Q2 Revenue Jumps 14 Percent ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Exagen Inc (NASDAQ:XGN) Surpasses Revenue Estimates in Q2 2025 Despite Wider Loss, Shares Rally in Pre-Market Trading ↗
Exagen Inc (XGN) beats Q2 2025 revenue estimates with $17.2M but posts wider loss. Stock jumps 6.77% pre-market as investors focus on growth potential. 
Via Chartmill
News headline image
Exagen Inc. Reports Strong Q2 2025 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Appoints Chas McKhann to Board of Directors
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Exagen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.